SCHEMBL8320356

SCHEMBL8320356

CN(C)c1ccc(-c2cnc3[nH]cc(-c4cnn(S(=O)(=O)c5ccccc5F)c4)c3c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.52
MAPK9 P45984 1/20 0.52
MAPK10 P53779 1/20 0.52
ALK Q9UM73 5/20 0.48
PIK3CD O00329 1/20 0.47
PIK3R1 P27986 1/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47
PIK3CG P48736 1/20 0.47
AXL P30530 4/20 0.46
MAP3K11 Q16584 1/20 0.44
NTRK1 P04629 1/20 0.44
CDK8 P49336 1/20 0.44
TNIK Q9UKE5 1/20 0.44
SGK1 O00141 3/20 0.43
CAMKK2 Q96RR4 2/20 0.43
PDPK1 O15530 1/20 0.43
KIT P10721 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8320848 0.92 MAPK8 (0.53) MAPK8MAPK9MAPK10ALKAXL
SCHEMBL12829887 0.89 MAPK8 (0.48) MAPK8MAPK9MAPK10ALKAXL
SCHEMBL8321704 0.88 MAPK8 (0.55) MAPK8MAPK9MAPK10ALKPIK3CD
SCHEMBL8319995 0.88 MAPK8 (0.49) MAPK8MAPK9MAPK10ALKAXL
SCHEMBL8320310 0.85 MAPK8 (0.60) MAPK8MAPK9MAPK10ALKAXL
SCHEMBL13745419 0.84 MAPK8 (0.54) MAPK8MAPK9MAPK10ALKAXL
SCHEMBL12829886 0.83 MAPK8 (0.56) MAPK8MAPK9MAPK10ALKAXL
SCHEMBL8321137 0.83 MAPK8 (0.52) MAPK8MAPK9MAPK10ALKAXL
SCHEMBL8317033 0.83 MAPK8 (0.58) MAPK8MAPK9MAPK10ALKAXL
SCHEMBL8317038 0.82 MAPK8 (0.47) MAPK8MAPK9MAPK10ALKAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
US-7432375-B2 JNK inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-10-07 US disclosed
WO-2004078756-A2 JNK INHIBITORS EISAI CO., LTD. (JP) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 MAPK8 50/4885MAPK9 43/4885MAPK10 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.